How to combine the two landmark treatment methods—allogeneic hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy together to …
M Zhang, H Huang - Frontiers in Immunology, 2020 - frontiersin.org
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has made tremendous
progress in the last few decades and is increasingly being used worldwide. The success of …
progress in the last few decades and is increasingly being used worldwide. The success of …
Axicabtagene ciloleucel in the management of follicular lymphoma: current perspectives on clinical utility, patient selection and reported outcomes
R Mohty, MA Kharfan-Dabaja… - Cancer Management and …, 2023 - Taylor & Francis
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor T-
cell therapy (CAR-T) that has shown efficacy in B-cell non-Hodgkin's lymphoma. It has …
cell therapy (CAR-T) that has shown efficacy in B-cell non-Hodgkin's lymphoma. It has …
A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent
JJ Scarisbrick, FL Dignan, S Tulpule… - Bone marrow …, 2015 - nature.com
DLIs are frequently used following haematopoietic SCT (HSCT) in patients with risk of
relapse but data on GVHD following DLI are scarce. We report on 68 patients who received …
relapse but data on GVHD following DLI are scarce. We report on 68 patients who received …
[HTML][HTML] Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow …
T Miyamoto, T Fukuda, M Nakashima, T Henzan… - Biology of Blood and …, 2017 - Elsevier
To evaluate the safety and efficacy of donor lymphocyte infusion (DLI), we retrospectively
analyzed 414 recipients who received unrelated DLI (UDLI) for the treatment of relapsed …
analyzed 414 recipients who received unrelated DLI (UDLI) for the treatment of relapsed …
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
P Chauvet, A Paviglianiti, M Labopin… - Bone marrow …, 2023 - nature.com
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell
transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of …
transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of …
The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review
R Puckrin, M Shafey, J Storek - Frontiers in Oncology, 2023 - frontiersin.org
Although the use of allogeneic hematopoietic cell transplantation (HCT) for chronic
lymphocytic leukemia (CLL) has declined with the development of novel targeted agents, it …
lymphocytic leukemia (CLL) has declined with the development of novel targeted agents, it …
[HTML][HTML] A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation
S Nikiforow, HT Kim, H Daley, C Reynolds… - …, 2016 - ncbi.nlm.nih.gov
Donor lymphocyte infusions are used to treat relapse after allogeneic hematopoietic stem
cell transplantation, but responses are inadequate. In addition to effector cells, infusions …
cell transplantation, but responses are inadequate. In addition to effector cells, infusions …
New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT
X Chang, X Zang, CQ Xia - Bone marrow transplantation, 2016 - nature.com
DLI is an effective strategy for patients with recurrent hematological malignancies after
allogeneic hematopoietic SCT (allo-HSCT). DLI has been widely applied to boost the graft …
allogeneic hematopoietic SCT (allo-HSCT). DLI has been widely applied to boost the graft …
Novel therapies for blastic plasmacytoid dendritic cell neoplasm
AA Lane - Hematology/Oncology Clinics, 2020 - hemonc.theclinics.com
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan, aggressive
hematologic malignancy of unmet clinical need. 1–3 Outcomes are poor, with median …
hematologic malignancy of unmet clinical need. 1–3 Outcomes are poor, with median …
Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma …
R Oostvogels, E Kneppers, MC Minnema… - Bone marrow …, 2017 - nature.com
Donor lymphocyte infusions (DLI) can induce durable remissions in multiple myeloma (MM)
patients, but this occurs rather infrequently. As the graft-versus-tumor (GvT) effect of DLI …
patients, but this occurs rather infrequently. As the graft-versus-tumor (GvT) effect of DLI …